Despite falling short of analyst expectations, Tyra Biosciences is taking its cancer drug to registrational development for ...

Also Read: ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug Specific key efficacy findings from cohort B (N=80) of the Phase 2/3 open-label, single-arm ...

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin significantly benefited patients with ...

SUZHOU, China, May 31, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented ...

"We thank the government for adding PADCEV in combination with pembrolizumab onto the PBS for first-line treatment of locally advanced or metastatic urothelial cancer, creating access to an ...

Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder cancer live longer while reducing the risk that their cancer will return ...

The five-year survival rate for all cancers combined has reached a historic 70%, according to the latest American Cancer Society Cancer Statistics 2026 report, based on all people diagnosed between ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

A large electronic health record study suggests that difficulty recognizing painless blood in urine may delay diagnosis and worsen long-term survival for bladder cancer patients with color vision ...

A retrospective cohort study suggested that people with color blindness may have a higher risk of mortality from bladder cancer compared with those who can see colors. The researchers hypothesized ...